Lipid profile of children with acute lymphoblastic leukemia during L-asparaginase treatment.

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Hippokratia Pub Date : 2023-04-01

M Ioannidou, C Avgeros, E Tsotridou, A Tragiannidis, A Galli-Tsinopoulou, K Makedou, E Hatzipantelis

{"title":"Lipid profile of children with acute lymphoblastic leukemia during L-asparaginase treatment.","authors":"M Ioannidou, C Avgeros, E Tsotridou, A Tragiannidis, A Galli-Tsinopoulou, K Makedou, E Hatzipantelis","doi":"","DOIUrl":null,"url":null,"abstract":"Background: L-asparaginase is valuable in treating pediatric acute lymphoblastic leukemia (ALL), yet its use has been associated with lipid profile disturbances.Methods: We compared the lipid profile [high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, apolipoprotein-α1 (Apo-Α1), apolipoprotein-B100 (Αpo-B100), lipoprotein-α (Lp-α), glucose, amylase, and lipase] between newly diagnosed ALL patients, ALL survivors, and healthy controls. We also assessed alterations of the parameters mentioned earlier during induction and consolidation treatment.Results: We recorded significant differences in the lipid profile at diagnosis of children with ALL compared to controls (HDL cholesterol, triglycerides, Apo-A1, and Apo-B100 levels). HDL cholesterol, total cholesterol, and Apo-Α1 levels increased significantly during induction at most time points. Levels of Αpo-B100, triglycerides, and Lp-α exhibited a downward trend. During re-induction, no change was observed. During the treatment of high-risk patients, we found no statistically significant difference for any of the examined variables.Conclusion: To confirm our preliminary results, the role of the administration of L-asparaginase and other medications in the variations in the lipid profile at diagnosis of children with ALL needs to be further elucidated with larger multicentre studies, including more patients from diverse ethnic backgrounds. HIPPOKRATIA 2023, 27 (2):41-47.","PeriodicalId":50405,"journal":{"name":"Hippokratia","volume":"27 2","pages":"41-47"},"PeriodicalIF":0.3000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268314/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hippokratia","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: L-asparaginase is valuable in treating pediatric acute lymphoblastic leukemia (ALL), yet its use has been associated with lipid profile disturbances.

Methods: We compared the lipid profile [high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, apolipoprotein-α1 (Apo-Α1), apolipoprotein-B100 (Αpo-B100), lipoprotein-α (Lp-α), glucose, amylase, and lipase] between newly diagnosed ALL patients, ALL survivors, and healthy controls. We also assessed alterations of the parameters mentioned earlier during induction and consolidation treatment.

Results: We recorded significant differences in the lipid profile at diagnosis of children with ALL compared to controls (HDL cholesterol, triglycerides, Apo-A1, and Apo-B100 levels). HDL cholesterol, total cholesterol, and Apo-Α1 levels increased significantly during induction at most time points. Levels of Αpo-B100, triglycerides, and Lp-α exhibited a downward trend. During re-induction, no change was observed. During the treatment of high-risk patients, we found no statistically significant difference for any of the examined variables.

Conclusion: To confirm our preliminary results, the role of the administration of L-asparaginase and other medications in the variations in the lipid profile at diagnosis of children with ALL needs to be further elucidated with larger multicentre studies, including more patients from diverse ethnic backgrounds. HIPPOKRATIA 2023, 27 (2):41-47.

本刊更多论文

急性淋巴细胞白血病患儿在接受 L-天冬酰胺酶治疗期间的血脂状况。

背景：L-天冬酰胺酶是治疗小儿急性淋巴细胞白血病（ALL）的重要药物，但其使用与血脂紊乱有关：我们比较了新诊断的ALL患者、ALL幸存者和健康对照组的血脂谱[高密度脂蛋白（HDL）胆固醇、低密度脂蛋白（LDL）胆固醇、总胆固醇、甘油三酯、载脂蛋白-α1（Apo-Α1）、载脂蛋白-B100（Αpo-B100）、脂蛋白-α（Lp-α）、葡萄糖、淀粉酶和脂肪酶]。我们还评估了诱导和巩固治疗期间上述参数的变化：结果：与对照组相比，我们发现ALL患儿在确诊时的血脂谱（高密度脂蛋白胆固醇、甘油三酯、载脂蛋白-A1和载脂蛋白-B100水平）存在明显差异。高密度脂蛋白胆固醇、总胆固醇和载脂蛋白-Α1的水平在大多数时间点的诱导过程中都显著增加。载脂蛋白-B100、甘油三酯和脂蛋白-α的水平呈下降趋势。在再次诱导期间，未观察到任何变化。在对高危患者的治疗过程中，我们没有发现任何受检变量在统计学上有显著差异：为了证实我们的初步研究结果，L-天冬酰胺酶和其他药物的应用在确诊为 ALL 儿童时血脂谱变化中的作用还需要通过更大规模的多中心研究（包括更多来自不同种族背景的患者）来进一步阐明。河马 2023，27 (2)：41-47。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hippokratia MEDICINE, GENERAL & INTERNAL-

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hippokratia journal is a quarterly issued, open access, peer reviewed, general medical journal, published in Thessaloniki, Greece. It is a forum for all medical specialties. The journal is published continuously since 1997, its official language is English and all submitted manuscripts undergo peer review by two independent reviewers, assigned by the Editor (double blinded review process). Hippokratia journal is managed by its Editorial Board and has an International Advisory Committee and over 500 expert Reviewers covering all medical specialties and additionally Technical Reviewers, Statisticians, Image processing Experts and a journal Secretary. The Society “Friends of Hippokratia Journal” has the financial management of both the printed and electronic edition of the journal.